Full-Time

Senior Microbiology Team Lead

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Minna, Inverin, Co. Galway, Ireland

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microbiology

Get referred to Viatris

See people who can refer or advise you

Requirements
  • Degree in Microbiology, Biological Sciences, Biotechnology, or related scientific discipline.
  • Significant experience within a GMP microbiology laboratory environment, preferably supporting sterile manufacturing, biologics, or aseptic processing operations.
  • Experience in a supervisory, team lead, or people management role within a regulated environment
  • Significant experience within a GMP pharmaceutical, sterile manufacturing, biologics, or medical device microbiology laboratory.
  • Strong experience in microbiological investigations, contamination control, environmental monitoring, and aseptic processing support.
  • Experience in microbial method validation/verification and laboratory equipment qualification.
  • Strong knowledge of EU GMP Annex 1, FDA Guidance for Aseptic Processing, USP/EP microbiological requirements, and Data Integrity expectations.
  • Experience leading teams and coordinating laboratory operations in a regulated environment.
  • Knowledge of Annex I and US and EMA GMP regulations.
  • Have working knowledge of isolator technology.
  • Have working knowledge of MODA.
  • Experience with sterile injectable products, aseptic manufacturing processes and contamination control strategies.
Responsibilities
  • Lead microbiology investigations including environmental monitoring, sterility failures, bioburden, endotoxin, and contamination events.
  • Drive root cause analysis, risk assessments, CAPAs, and effectiveness checks for microbiological deviations and quality issues.
  • Ensure compliance with GMP, GLP, Data Integrity, and regulatory standards across all laboratory activities.
  • Oversee validation and lifecycle management of microbiological methods, equipment qualification (IQ/OQ/PQ), and method transfers.
  • Review and approve microbiology documentation, including test results, environmental monitoring data, and investigation reports.
  • Support and continuously improve the Environmental Monitoring (EM) program for manufacturing and aseptic areas.
  • Lead and maintain microbiology quality systems, including SOPs, change controls, deviations, and trend reporting.
  • Provide technical leadership, mentoring, and training to microbiology team members.
  • Manage laboratory operations, including resource planning and prioritisation, to meet business needs.
  • Support audits and inspections, representing the microbiology function and ensuring timely follow-up actions.
  • Drive continuous improvement initiatives and operational excellence within the laboratory.
  • Act as deputy to the Microbiology Laboratory Manager when required.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $3.76 billion, and management raised full-year guidance.
  • Gross leverage fell to 2.9x after repaying $900 million debt in Q2.
  • FDA accepted MR-107A-02, with a December 27, 2026 PDUFA driving new growth.

What critics are saying

  • Nashik fire and FDA Form 483 disruptions cut second-half 2026 revenue by $100 million-$150 million.
  • Tyrvaya rights sale and $177.8 million write-down signal shrinking eye-care ambitions.
  • Novo Nordisk's Wegovy patent fight and generic pricing pressure threaten future margins.

What makes Viatris unique

  • Viatris sells in 165 countries, giving unmatched global reach for generic launches.
  • Greater China execution and e-commerce lifted Q2 2026 growth despite pricing pressure.
  • FDA approval of Gwyn Lo and Effexor Japan expansion broaden branded pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Aug 11th, 2026
Viatris beats Q2 estimates with $3.76B revenue, ups full-year guidance amid China growth and margin pressures

Viatris reported second-quarter revenue of $3.76 billion, up 4.9% year-on-year and beating analyst estimates of $3.68 billion. The medication company's non-GAAP earnings per share of $0.69 exceeded forecasts by 15%. CEO Scott Smith attributed the performance to strong commercial execution in Greater China, where investments in established brands and e-commerce drove double-digit growth. Demand for cardiovascular products and higher-margin generics in North America also contributed. The company raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 5% increase, whilst lifting revenue guidance slightly to $14.75 billion. However, operating margin fell to 0.2% from 6.5% in the prior-year quarter. Management noted supply chain disruptions and lower-margin products in emerging markets as headwinds, alongside manufacturing challenges and policy changes in China.

PR Newswire
Aug 6th, 2026
Viatris reports Q2 revenues of $3.8B, up 5%, raises 2026 guidance despite $119M loss

Viatris reported second-quarter 2026 revenues of $3.8 billion, representing 5% reported growth compared to the same period in 2025. The pharmaceutical company posted a US GAAP net loss of $119 million, primarily driven by a non-cash charge of $177.8 million related to the planned sale of Tyrvaya product rights. Adjusted EBITDA reached $1.2 billion, up 8% operationally year-over-year. The company returned approximately $550 million to shareholders, including roughly $270 million through share repurchases at a weighted average price of $16.42 per share. Viatris reduced its gross leverage ratio to 2.9x after repaying approximately $900 million in debt. The company raised its full-year 2026 financial guidance midpoints across all metrics. In July, Viatris received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch expected to launch later this year.

Yahoo Finance
Aug 2nd, 2026
Viatris wins FDA approval for Gwyn Lo contraceptive patch

Viatris has received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch. The product adds a new branded option to the company's women's health portfolio. Gwyn Lo's approval comes as Viatris shares have shown strong momentum. The stock currently trades at $17.56, reflecting a 40.9% year-to-date return and 107.2% gain over the past year. The contraceptive patch may help diversify Viatris' revenue mix. Investors will be watching how quickly the product gains traction in prescribing patterns and market share. The company's shares trade close to the analyst price target of $17.94. However, Viatris carries a high forward price-to-earnings ratio of 57.84, and its 2.73% dividend yield is reportedly not well covered by earnings.

TipRanks
Jul 1st, 2026
Viatris secures $260M term loan facility to refinance debt and support operations

Viatris has secured a ¥40 billion (approximately $270 million) unsecured term loan facility with a syndicate of lenders led by Mizuho Bank. The three-year facility, which closed on 1 July 2026, will support general corporate purposes and refinance a prior loan of the same amount. The facility is priced at the TIBO Rate plus 1.10%, with pricing linked to Viatris' long-term credit ratings. It includes leverage ratio limits, standard covenants on indebtedness, dividends and mergers, plus default provisions allowing lenders to accelerate repayment. The loan is backed by guarantees from key Viatris subsidiaries and allows penalty-free prepayments, providing the pharmaceutical company with liquidity in the Japanese market whilst maintaining financial flexibility.

Yahoo Finance
Jun 14th, 2026
Viatris raises euro debt to reshape capital structure amid insider selling and growth questions

Viatris has completed a euro-denominated senior unsecured notes offering, adding new capital and euro currency debt to its balance sheet. The global pharmaceutical company, which operates across branded, generic and biosimilar medicines, has not disclosed the size or terms of the transaction. The offering follows recent insider selling and questions about the company's growth trajectory. The fresh capital provides flexibility for future refinancing, acquisitions, divestitures or internal investment decisions. At $16.48, Viatris shares trade 7.9% below the $17.81 analyst target. The stock pays a 2.91% dividend, though analysts have flagged concerns about dividend coverage. Investors will be monitoring how management allocates capital between debt reduction, acquisitions and shareholder returns, particularly given the increased interest costs from the new euro debt.